



PT IKAPHARMINDO PUTRAMAS Tbk
Pharmaceutical Laboratories

("Company")

ANNOUNCEMENT
SUMMARY OF MINUTES OF ANNUAL GENERAL MEETING OF
SHAREHOLDERS

The Board of Directors of the Company hereby announces to the Shareholders of the Company that the Company has held an Annual General Meeting of Shareholders ("AGMS") In order to comply with the Financial Services Authority Regulation No.15/POJK.04/2020 concerning the Plan and Implementation of the General Meeting of Shareholders of Public Companies, the Company submitted a summary of the minutes of the AGMS as follows:

AGMS

Annual General Meeting of Shareholders, on:

Day/date : Monday, 27 May 2024.

Place : Cengkir Room
Kelapa Gading Club
Jalan Bulevar Kelapa Gading Block KGC
Summarecon Kelapa Gading
Jakarta, 14240, Indonesia.

Time : 10.25 – 11.14 WIB.

Agenda :

1. Approval and ratification of the Company's Annual Report for the 2023 financial year, including the Company's Activity Report, the Board of Commissioners' Supervisory Report and the Company's Financial Statements for the 2023 financial year, as well as the granting of full repayment and release of responsibility (*Acquit and discharge*) to the Board of Directors and Board of Commissioners of the Company for their management and supervisory actions in the 2023 financial year.
2. Determination of the use of the Company's Net Profit for the 2023 financial year.
3. Report and accountability for the realization of the use of funds from the Public Offering.
4. Appointment of a Public Accountant and/or Public Accountant Firm to audit the Company's Financial Statements for the financial year ended December 31, 2024, and authorization to determine the honorarium of the Public Accountant and/or Public Accountant Firm and other requirements.
5. Determination of honorarium, salary and other benefits for members of the Company's Board of Commissioners and Board of Directors.

(herein after referred to as Meetings).

For the benefit of the Company, a deed of Minutes of the Company's Annual General Meeting of Shareholders was made, dated May 27, 2024, with number 137.

Presence of members of the Board of Directors and Board of Commissioners of the Company:

Members of the Board of Directors who attended the Meeting:

President Director : Mr. KARTONO;
Director : Mr. AYI SAEPUDIN;
Director : Mrs. Eliza Arlena Winata;

Members of the Board of Commissioners who attended the Meeting:

President Commissioner : Mrs. MAUDY RATNA WINATA;
Independent Commissioner : Mr. SUSANTO LAM.

Meeting Chair:

-The meeting was chaired by Mr. SUSANTO LAM, as the Company's Independent Commissioner.

Presence of Shareholders:

-The Meeting has been attended by shareholders and shareholders' proxies representing 1,472,138,000 shares or representing 87.38% of 1,684,662,500 shares which are all shares with valid voting rights issued by the Company after deducting the number of shares that have been repurchased by the Company.

Submission of Questions and/or Opinions:

-Shareholders and shareholders' proxies are given the opportunity to ask questions and/or opinions for each agenda of the Meeting, but none of the shareholders and shareholders' proxies ask questions and/or opinions;

Decision Making Mechanism:

-Decision making of all agendas is carried out based on deliberation for consensus, in the event that deliberation for consensus is not reached, decision making is carried out by voting.

Voting Results:

First Agenda:

-Number of blank votes/abstentions : 138.067.800 votes.
-Number of dissenting votes : - voice.
-Number of affirmative votes : 1.334.070.200 votes.
-So that the total votes are affirmative : 1,472,138,000 votes, or by 100%, or 100%

Number of blank/abstention votes	Number of votes disagree	Number of affirmative votes	Total affirmative votes	(%)
138.067.800	-	1.334.070.200	1.472.138.000	100%

Second Agenda:

- Number of blank votes/abstentions : 138.067.800 votes.
- Number of dissenting votes : - voice.
- Number of affirmative votes : 1.334.070.200 votes.
- So that the total votes are affirmative : 1,472,138,000 votes, or by 100%, or 100%

Number of blank/abstention votes	Number of votes disagree	Number of affirmative votes	Total affirmative votes	<u>(%)</u>
138.067.800	-	1.334.070.200	1.472.138.000	100%

Third Agenda:

- Number of blank votes/abstentions : 138.067.800 votes.
- Number of dissenting votes : - voice.
- Number of affirmative votes : 1.334.070.200 votes.
- So that the total votes are affirmative : 1,472,138,000 votes, or by 100%, or 100%

Number of blank/abstention votes	Number of votes disagree	Number of affirmative votes	Total affirmative votes	<u>(%)</u>
138.067.800	-	1.334.070.200	1.472.138.000	100%

Fourth Agenda:

- Number of blank votes/abstentions : 138.067.800 votes.
- Number of dissenting votes : - voice.
- Number of affirmative votes : 1.334.070.200 votes.
- So that the total votes are affirmative : 1,472,138,000 votes, or by 100%, or 100%

Number of blank/abstention votes	Number of votes disagree	Number of affirmative votes	Total affirmative votes	<u>(%)</u>
138.067.800	-	1.334.070.200	1.472.138.000	100%

Fifth Agenda:

- Number of blank votes/abstentions : 138.067.800 votes.
- Number of dissenting votes : 200 votes.
- Number of affirmative votes : 1.334.070.000 votes.
- So that the total votes are affirmative : 1,472,137,800 votes, or 99.999%, or 99,99%

Number of blank/abstention votes	Number of votes disagree	Number of affirmative votes	Total affirmative votes	<u>(%)</u>
138.067.800	200	1.334.070.000	1.472.137.800	99,99%

Meeting Decision:**First Agenda Decision:**

- Approve and ratify the Company's Annual Report for the 2023 financial year, including the Company's Activity Report, the Board of Commissioners' Supervisory Task Report and the Company's Financial Statements for the 2023 financial year, as well as provide full repayment and release of responsibility (*Acquit and discharge*) to the Board of Directors and Board of Commissioners of the Company for their management and supervisory actions, to the extent such actions are reflected in the Company's Annual Report.

Second Agenda Decision:

- a. Approve the use of the Company's net profit for the 2023 financial year as follows:
 - i. amounting to Rp3,790,490,625.00 (three billion seven hundred ninety million four hundred ninety thousand six hundred twenty-five rupiah) or 24.71% (twenty four point seven one percent) of the Company's net profit for the 2023 financial year, distributed as cash dividends to the Company's shareholders so that each share will receive a cash dividend of Rp2, 25 (two point two five rupiah);
 - ii. amounting to Rp2,000,000,000.00 (two billion rupiah), set aside and recorded as a reserve fund;
 - iii. the rest is recorded as retained earnings, to increase the Company's working capital;
- b. Grant power and authority to the Board of Directors of the Company to take any and all necessary actions in connection with the above decisions, in accordance with applicable laws and regulations.

Third Agenda Decision:

- Receive a good report on the realization of the use of funds from the Company's Initial Public Offering.

Fourth Agenda Decision:

- Grant authority and power to the Board of Commissioners of the Company, to appoint a Public Accountant and/or Public Accountant Firm, with Independent criteria and registered with the Financial Services Authority, who will audit the Company's financial statements for the financial year 2024 as they are being considered and evaluated for the appointment of a Public Accountant and/or Public Accountant Firm further, taking into account the recommendations of the Audit Committee, and to determine the honorarium of the Public Accountant along with the conditions of his appointment including dismissal or appointment of a replacement.

Fifth Agenda Decision:

- a. Determine honorarium, salary, and other benefits for the Company's Board of Commissioners as a whole for the 2024 financial year, in an amount equal to the amount of salary and other benefits provided in the 2023 financial year, or if there is an increase, the amount of increase does not exceed 6% (six percent) of the amount of salary and other benefits provided in the 2023 financial year, and authorize the Board of Commissioners Meeting to determine its allocation, taking into account the recommendations of the Nomination and Remuneration Committee.
- b. Authorize the Board of Commissioners of the Company to determine remuneration in the form of salary and other benefits for the Board of Directors of the Company, taking into account the recommendations of the Nomination and Remuneration Committee.

Jakarta, 29th May 2024
Management
PT Ikapharmindo Putramas Tbk